Long-term follow-up for ARD103 CAR-T cell therapy patients
Part of Blood & lymphatic, Cancer clinical trials.
This study follows patients who have already received ARD103 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to monitor their health over time without giving any new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsed or refractory AML or MDS
- You have already received ARD103 CAR-T cell therapy in a previous study
- You can understand and agree to the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
This study tests a special immune cell therapy (CAR T-cells) that targets two proteins on leukemia cells. It is for people whose AML has returned or not responded to standard treatments.
This trial tests a new treatment, CT1390B, for people whose acute myeloid leukemia (AML) has come back or not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.